AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer ...

The author includes U.S. and Canadian names, organized by country. Each company comes with a business summary, plus a bull ...

The global Botulinum Toxins Market, valued at US$8.1 billion in 2024 stood at US$8.9 billion in 2025 and is projected to advance at a ...

All in all, I rated AbbVie a Buy based on its leadership in immunology, strategic expansion into oncology and neuroscience, and an undervalued stock.

AbbVie Inc. (NYSE:ABBV) is one of the 12 best healthcare stocks to buy now. On June 12, the US Food and Drug Administration (FDA) approved the company’s Mavyret treatment label expansion.

The pharma began its outreach to the HS community well before securing Bimzelx’s approval in the indication. In the spring of ...